For healthcare professionals only

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

It is important to undertake medication reviews of your adult patients with type 2 diabetes who wish to fast during Ramadan.

Proven efficacy vs placebo1,6

Proven efficacy vs placebo.1,6 The efficacy and safety of 5 mg linagliptin was evaluated in eight phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator1

Demonstrated CV and kidney safety profile

Long-term cardiovascular and kidney safety profile of TRAJENTA® has been emonstrated in two cardiovascular outcome trials.7-12 As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with type 2 diabetes independent of renal function.1

Unique convenience of one dose, once daily1

The recommended dose of TRAJENTA® for adult patients with type 2 diabetes is 5 mg once daily, independent of renal and hepatic function, body mass index, age, ethnicity, background type 2 diabetes therapy, and disease duration1,13


How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

Join our faculty as they discuss the role of clinical inertia in the suboptimal achievement of treatment targets and share practical tips for addressing this topic with your adult type 2 diabetes patients

The event starts in:

  1. 1. TRAJENTA® (linagliptin) Summary of Product Characteristics (SmPC).*
  2. Sitagliptin SmPC.*
  3. Vildagliptin SmPC.*
  4. Saxagliptin SmPC.*
  5. Alogliptin SmPC.**
  6. McGill JB, et al. Diabetes Care. 2013;36:237–44.
  7. Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
  8. Rosenstock J, et al. JAMA 2019;321:69–79.
  9. Cooper M, et al. Diabetes Obes Metab. 2020;22:1062–73.
  10. Marx N, et al. Diab Vasc Res. 2015;12:164–74.
  1. Rosenstock J, et al. JAMA. 2019;322:1155–66.
  2. Espeland MA, et al. Diabetes Obes Metab 2021;23:569–80.
  3. Lajara R, et al. Clin Ther. 2014;36:1595–605.


*Summary of Product Characteristics for Trajenta, sitagliptin, vildagliptin and saxagliptin are available at: (GB), (NI) and (ROI).

**Summary of Product Characteristics for alogliptin are available at: (GB) and (NI).

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at (UK) or (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail:

PC-GB-106627 V2 | March 2023

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.

You are leaving this site.

You are now leaving
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

For healthcare professionals only

Are you a healthcare professional?

The information is intended for healthcare professionals only.
Please confirm below.